Indicators Affecting PVT Recanalization

NCT07473375 | Recruiting

• 1 other identifier: CSY-PVT-anticoagulation
• Study Type: observational
• Target: 1,500
• Locations: 1 country
• Sites: 1

Brief Summary

This is a retrospective-prospective study conducted at Zhongshan Hospital, Fudan University, to explore portal vein thrombosis (PVT) in patients with cirrhosis and gastroesophageal varices (GEV). It aimed to provide insights into the diagnosis, follow-up, and factors influencing PVT recanalization, to help patients, families, and healthcare providers understand the disease and related clinical management.

Conditions

Portal Vein Thrombosis; Cirrhosis; Portal Hypertension Related to Cirrhosis; Portal Hypertension, Noncirrhotic

Outcome Measures

Primary Outcomes (1)

• PVT recanalization at 1 year

  From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 1 year, death, or the last follow-up, whichever came first

Secondary Outcomes (3)

• Occurrence of all-cause death (competing event)

  From the date of admission confirmation of PVT to the occurrence of death, or the last follow-up, whichever came first

• PVT recanalization at 5 years

  From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 5 year, death, or the last follow-up, whichever came first

• Occurrence of non-improved PVT

  From the date of admission confirmation of PVT to the last radiological follow-up at 1 year, or death, whichever came first

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study enrolled adult patients with cirrhosis and confirmed gastroesophageal varices who presented to Zhongshan Hospital, Fudan University, and were diagnosed with portal vein thrombosis (PVT)upon admission.

You may qualify if:

• diagnosed as cirrhosis and confirmed gastroesophageal varices by endoscopy;
• all patients were diagnosed as PVT by CTA at admission.

You may not qualify if:

• patients with hepatocellular carcinoma;
• patients with extrahepatic malignancies;
• history of liver transplantation or TIPS;
• lack of information regarding anticoagulation therapy；
• those with cavernous transformation of the portal vein(CTPV) .

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead

Study Sites (1)

Unknown Facility

Shanghai, Shanghai Municipality, 200032, China

RECRUITING

MeSH Terms

Conditions

Fibrosis; Hypertension, Portal

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Liver Diseases; Digestive System Diseases

Central Study Contacts

Siyu Jiang, Dr.

CONTACT

+86-15121068078; ksjsy1996926@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 11, 2026
• First Posted: March 16, 2026
• Study Start: January 1, 2017
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: March 16, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)